The effect of Benzothiazolone‐2 on the expression of Metallothionein‐3 in modulating Alzheimer's disease. Issue 9 (15th August 2017)
- Record Type:
- Journal Article
- Title:
- The effect of Benzothiazolone‐2 on the expression of Metallothionein‐3 in modulating Alzheimer's disease. Issue 9 (15th August 2017)
- Main Title:
- The effect of Benzothiazolone‐2 on the expression of Metallothionein‐3 in modulating Alzheimer's disease
- Authors:
- Roy, Sudeep
Gumulec, Jaromir
Kumar, Akhil
Raudenska, Martina
Baig, Mohd Hassan
Polanska, Hana
Balvan, Jan
Gupta, Mansi
Babula, Petr
Odstrčilík, Jan
Choi, Inho
Provaznik, Ivo
Masarik, Michal - Abstract:
- Abstract: Introduction: Metallothioneins (MTs) are a class of ubiquitously occurring low‐molecular‐weight cysteine‐ and metal‐rich proteins containing sulfur‐based metal clusters. MT‐3 exhibits neuro‐inhibitory activity. The possibility to enhance the expression of MT‐3 or protect it from degradation is an attractive therapeutic target, because low levels of MT‐3 were found in brains of Alzheimer's disease (AD) patients. Objectives: The primary objective of this study was to test an enhancement of MT‐3 cellular concentration after MT‐3 binding treatment, which could prevent MT‐3 degradation. Methods: MTT assay, flow‐cytometry, fluorescence microscopy, quantitative real‐time polymerase chain reaction, and immunodetection of MT3 were used for analysis of effect of STOCK1N‐26544, STOCK1N‐26929, and STOCK1N‐72593 on immortalized human microglia‐SV40 cell line. Results: All three tested compounds enhanced concentration of MT‐3 protein in cells and surprisingly also mRNA concentration. IC50 values of tested molecules exceeded about ten times the concentration that was needed for induction of MT‐3 expression. The tested compound Benzothiazolone‐2 enhanced apoptosis and necrosis, but it was not of severe effect. About 80% of cells were still viable. There was no serious ROS‐generation and no severe decrease in mitochondria numbers or stress induced endoplasmic reticulum changes after test treatments. The selected compound showed stable hydrophobic and electrostatic interactionAbstract: Introduction: Metallothioneins (MTs) are a class of ubiquitously occurring low‐molecular‐weight cysteine‐ and metal‐rich proteins containing sulfur‐based metal clusters. MT‐3 exhibits neuro‐inhibitory activity. The possibility to enhance the expression of MT‐3 or protect it from degradation is an attractive therapeutic target, because low levels of MT‐3 were found in brains of Alzheimer's disease (AD) patients. Objectives: The primary objective of this study was to test an enhancement of MT‐3 cellular concentration after MT‐3 binding treatment, which could prevent MT‐3 degradation. Methods: MTT assay, flow‐cytometry, fluorescence microscopy, quantitative real‐time polymerase chain reaction, and immunodetection of MT3 were used for analysis of effect of STOCK1N‐26544, STOCK1N‐26929, and STOCK1N‐72593 on immortalized human microglia‐SV40 cell line. Results: All three tested compounds enhanced concentration of MT‐3 protein in cells and surprisingly also mRNA concentration. IC50 values of tested molecules exceeded about ten times the concentration that was needed for induction of MT‐3 expression. The tested compound Benzothiazolone‐2 enhanced apoptosis and necrosis, but it was not of severe effect. About 80% of cells were still viable. There was no serious ROS‐generation and no severe decrease in mitochondria numbers or stress induced endoplasmic reticulum changes after test treatments. The selected compound showed stable hydrophobic and electrostatic interaction during MT‐3 ligand interaction. Conclusion: Benzothiazolone‐2 compounds significantly enhanced MT‐3 protein and mRNA levels. The compounds can be looked upon as one of the probable lead compounds for future drug designing experiments in the treatment of Alzheimer's disease. Abstract : Benzathiazolone‐2 modulates the concentration of Metallothionein‐3 which is important in delaying the onset of Alzheimer's disease. Benzathiozolone‐2 is a natural molecule obtained from Micrococcus sp. found in Tedania ignis. It is also obtained from plants, such as Acacia spp., Lens esculenta, Prosopsis juliflora, as well as from the fungi Ponaeolus foenisicii, Coprinus micaceus and from the gorgonian Paramuricia chamaeleon. … (more)
- Is Part Of:
- Brain and behavior. Volume 7:Issue 9(2017)
- Journal:
- Brain and behavior
- Issue:
- Volume 7:Issue 9(2017)
- Issue Display:
- Volume 7, Issue 9 (2017)
- Year:
- 2017
- Volume:
- 7
- Issue:
- 9
- Issue Sort Value:
- 2017-0007-0009-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2017-08-15
- Subjects:
- Alzheimer's disease -- flow cytometry -- immunodetection -- metallothionein‐3 -- molecular dynamics -- qRT‐PCR
Neurology -- Periodicals
Neurosciences -- Periodicals
Psychology -- Periodicals
Psychiatry -- Periodicals
616.8005 - Journal URLs:
- http://bibpurl.oclc.org/web/52745 \u http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2157-9032 ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2157-9032 ↗
http://www.ncbi.nlm.nih.gov/pmc/journals/1650 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/brb3.799 ↗
- Languages:
- English
- ISSNs:
- 2162-3279
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4653.xml